8227 0.0127 0.9091 AUC0–inf 0.8255 0.0099 0.9010 C max 0.5835 0.1291 0.8606 AUC 0–inf area under the serum concentration–time curve from time zero to infinity AUC 0–t area under the serum concentration–time curve from time zero to time of last measurable concentration, C max maximum serum concentration Fig. 2 Mean plasma ibandronic acid concentrations obtained for the test and reference formulations following a 150-mg dose (log scale). N = 146 for ibandronic acid, N = 146 for

Bonviva® (first administration), N = 142 for Bonviva® (second administration), EDTA Ethylene diaminetetraacetic acid The CVWR for AUC0–t , AUC0–inf and C max were 39.77, 39.45 and 43.23 %, respectively. The limits of the acceptance range PLK inhibitor based upon the within-subject variability seen in the bioequivalence study using scaled Thiazovivin research buy average bioequivalence were 73.01–136.97 %. No statistical outliers were detected for the reference formulation following examination ARRY-438162 ic50 of the distribution of the ln-transformed C max. The 90 % confidence intervals were 95.05–110.67 for

C max, 94.35–107.94 for AUC0–t and 94.37–107.88 for AUC0–inf, which are within the predefined bioequivalence acceptance range of 80.00–125.00 %. For C max, the observed ratio and confidence intervals were also within the limits of acceptance obtained using the scaled average bioequivalence BCKDHB approach. Wilcoxon’s test performed on the

t max data showed no statistically significant difference between treatments (p = 0.1382). The least-squares means ratios, the 90 % geometric confidence intervals, and the CVWR for the reference product are presented in Table 4. Table 4 Ibandronic acid: ratios, 90 % geometric confidence intervals (CI) for AUC0–t , AUC0–inf and C max and intra-subject CV for Bonviva® Variable Treatment comparisons Ratioa (%) 90 % CIb (%) Intra-subject CV (Bonviva®) (%) AUC0–t Test (A)—reference (B) 100.92 94.35–107.94 39.77 AUC0–inf Test (A)—reference (B) 100.90 94.37–107.88 39.45 C max c Test (A)—reference (B) 102.56 95.05–110.67 43.23 aCalculated using least-squares means b90 % geometric confidence interval using ln-transformed data cThe scaled average bioequivalence approach was used for C max and the widened limits obtained were 73.01–136.97 % AUC 0–inf area under the serum concentration–time curve from time zero to infinity AUC 0–t area under the serum concentration–time curve from time zero to time of last measurable concentration, C max maximum serum concentration, CV coefficient of variance 3.